Clinical trials: Early Diffuse Cutaneous Systemic Sclerosis
Diffuse Cutaneous Systemic Sclerosis
Efficacy and Safety of Telitacicept in the Treatment of Systemic Sclerosis
This study is a prospective, open-label, randomized, controlled, multi-center clinical trial. The aim of this study is to investigate the efficacy and safety of Telitacicept in adults with early diffuse cutaneous systemic…
- Trial name
- NCT06375005
- Testing
- Telitacicept, Mycophenolate Mofetil
- Where
- 9 sites in China
- Volunteers
- 38 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Diffuse Cutaneous Systemic Sclerosis
Open Label Extension Study of Brentuximab Vedotin in Early dcSSc
The purpose of this study is to assess safety and efficacy of Brentuximab vedotin, a CD30-directed antibody-drug conjugate, in patients with active diffuse cutaneous systemic sclerosis (dcSSc) who relapsed after discontinuation…
- Trial name
- NCT05149768
- Testing
- Brentuximab vedotin
- Where
- Canada
- Volunteers
- 3 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Healthy, Systemic Sclerosis
Systemic Sclerosis Clinical and Biomarker Study
The primary objective of the study is to assess the change in systemic sclerosis (SSc)-associated gastrointestinal (GI) tract symptoms over a 1-year period in participants with SSc.
- Trial name
- NCT02531009
- Volunteers
- healthy volunteers welcome
- Sponsor
- Biogen
Diffuse Cutaneous Systemic Sclerosis
Brentuximab Vedotin in Early Diffuse Cutaneous Systemic Sclerosis
The purpose of this study is to assess feasibility, safety and preliminary efficacy of Brentuximab vedotin (Adcetris), a CD30-directed antibody-drug conjugate, in the treatment of active diffuse cutaneous systemic sclerosis…
- Trial name
- NCT03198689
- Testing
- Brentuximab Vedotin
- Where
- Canada
- Volunteers
- 11 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Early Diffuse Cutaneous Systemic Sclerosis
Treatment Outcome in Early Diffuse Cutaneous Systemic Sclerosis
The aim of the study is to compare the effectiveness of commonly used immunosuppressant treatments for early diffuse cutaneous systemic sclerosis (SSc).
- Trial name
- ESOS (NCT02339441)
- Testing
- Methotrexate, Mycophenolate mofetil, Cyclophosphamide
- Volunteers
- 320 people
- Sponsor
- University of Manchester
Systemic Sclerosis, Scleroderma
Evaluation of Tofacitinib in Early Diffuse Cutaneous Systemic Sclerosis (dcSSc)
This Phase I/II placebo controlled trial will evaluate tofacitinib in subjects with diffuse cutaneous systemic scleroderma (dcSSc).
- Trial name
- TOFA-SSc (NCT03274076)
- Testing
- Tofacitinib
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- University of Michigan
Diffuse Cutaneous Systemic Sclerosis
Extracorporeal Photopheresis in Early Diffuse Cutaneous Systemic Sclerosis
The purpose of this study is to assess feasibility, safety and preliminary efficacy of Extracorporeal Photopheresis in the treatment of active diffuse cutaneous systemic sclerosis (dcSSc).
- Trial name
- NCT04986605
- Testing
- Extracorporeal Photopheresis (ECP), UVADEX
- Where
- Canada
- Volunteers
- 15 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Systemic Sclerosis, Scleroderma
Safety, Tolerability, and Pharmacokinetics of CAT-192 (Human Anti-TGF-Beta1 Monoclonal Antibody) in Patients With Early Stage Diffuse Systemic Sclerosis
Systemic Sclerosis (also known as Scleroderma) is a chronic, autoimmune disease of the connective tissue generally classified as one of the rheumatic diseases.
- Trial name
- NCT00043706
- Testing
- Human Anti-Transforming Growth Factor Beta-1 Monoclonal Antibody
- Where
- 4 sites in United States
- Sponsor
- Genzyme, a Sanofi Company
Systemic Sclerosis
Prednisolone in Early Diffuse Systemic Sclerosis
This is a randomised placebo-controlled study of moderate dose prednisolone for 6 months in patients with early diffuse cutaneous systemic sclerosis (dcSSc).
- Trial name
- PRedSS (NCT03708718)
- Testing
- Prednisolone 5 mg
- Where
- 14 sites in United Kingdom
- Volunteers
- 35 people
- Sponsor
- Prof. Ariane herrick
Scleroderma, Diffuse
High Dose Intravenous N-Acetylcysteine Versus Iloprost for Early, Rapidly Progressive Diffuse Systemic Sclerosis
Systemic sclerosis (scleroderma; SSc) is a rare, disfiguring systemic disorder characterized by fibrosis of the skin and visceral organs that alters every aspect of an individual life Although some features of scleroderma…
- Trial name
- NCT00428883
- Testing
- N-acetylcysteine (NAC)
- Where
- 5 sites in Italy
- Volunteers
- 45 people
- Sponsor
- Università Politecnica delle Marche
Systemic Sclerosis, Systemic Scleroses, Diffuse
Upfront Autologous HSCT Versus Immunosuppression in Early Diffuse Cutaneous Systemic Sclerosis
HSCT has been implemented in (inter)national treatment guidelines for diffuse cutaneous systemic sclerosis (dcSSc) and is offered in clinical care and reimbursed by national health insurance in several European countries.
- Conditions
- Systemic Sclerosis, Systemic Scleroses, Diffuse, Scleroderma, Scleroderma, Diffuse
- Trial name
- UPSIDE (NCT04464434)
- Testing
- Upfront autologous HSCT
- Where
- 8 sites in Italy, Netherlands and 1 more
- Volunteers
- 60 people
- Sponsor
- UMC Utrecht
Scleroderma
Atorvastatin for Microvascular Endothelial Function and Raynaud in Early Diffuse Scleroderma
The purpose of this study is to learn about the effect atorvastatin on blood vessel function and Raynaud symptoms in patients with early diffuse systemic sclerosis.
- Trial name
- TAMER (NCT02370784)
- Testing
- atorvastatin
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Robyn T. Domsic, MD, MPH
Systemic Sclerosis
Belimumab for the Treatment of Diffuse Cutaneous Systemic Sclerosis
This is a 48 week, phase IIa, single center, randomized, double-blind, placebo-controlled, proof-of-concept pilot study. All participants will first be treated with mycophenolate mofetil (MMF, Cellcept) and titrated up to a dose…
- Trial name
- NCT01670565
- Testing
- Belimumab, Mycophenolate Mofetil
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Hospital for Special Surgery, New York